BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 12152004)

  • 1. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
    Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
    Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
    Schwartz JI; Thach C; Lasseter KC; Miller J; Hreniuk D; Hilliard DA; Snyder KM; Gertz BJ; Gottesdiener KM
    J Clin Pharmacol; 2007 Dec; 47(12):1521-31. PubMed ID: 17925592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
    Whelton A
    J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial.
    Malmstrom K; Daniels S; Kotey P; Seidenberg BC; Desjardins PJ
    Clin Ther; 1999 Oct; 21(10):1653-63. PubMed ID: 10566562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
    Clària J; Kent JD; López-Parra M; Escolar G; Ruiz-Del-Arbol L; Ginès P; Jiménez W; Vucelic B; Arroyo V
    Hepatology; 2005 Mar; 41(3):579-87. PubMed ID: 15723448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
    Ta LE; Dionne RA
    Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
    Wolfe F; Zhao S; Pettitt D
    J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
    Hinz B; Dormann H; Brune K
    Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.